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Preface 
The report arising from the first comprehensive study of health expenditures by 
disease in Australia, using estimated expenditures by disease in 1993–94 was 
released in September 1998.  The study involved a comprehensive accounting of 
disease costs across all chapters of the International Classification of Diseases Ninth 
Revision (ICD-9) (AIHW: Mathers et al. 1998a). 
This report updates these numbers to 2000–01.  The methodology has been revised in 
some areas and the analysis made across the disease and injury groups used in the 
first Australian Burden of Disease study (AIHW: Mathers et al. 1999). The underlying 
data use the ICD-10 Classification of Diseases and the International Classification of 
Primary Care Version 2 (ICPC 2).  
The report provides an overview of total health system expenditures on disease and 
injury in Australia during 2000–01, based on the best possible estimates from 
currently available data sources.  To maximise the validity of comparison between 
diseases, the same methods are used in estimating each disease. It is recognised that 
for disease-specific analyses it is sometimes necessary to draw data from diverse 
disease groups in order to estimate the full impact of a disease. In examining diabetes 
for example, it is often useful to estimate the proportion of heart and renal disease 
costs that can reasonably be attributed to diabetes. In this report, however, each 
health dollar is allocated to just one disease, so the total for all diseases adds to the 
total expenditure in the health system that is allocated by disease.  
These numbers provide a useful picture of health expenditure according to the 
clinically relevant category of disease.  However, they should not be the sole 
determining factor in resource allocation decisions. The existing expenditure on a 
disease, no matter how large or small, does not in itself give an indication of the loss 
of health due to that disease, or the priority for intervention or need for additional 
health services expenditure. Resource allocation decisions require information not 
only on average costs and outcomes but also on the marginal costs and marginal 
outcomes associated with the specific interventions under consideration.  
 
 
 
Richard Madden 
Director 
Australian Institute of Health and Welfare 
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Executive summary   
This report provides a systematic analysis of Australian health expenditure allocated 
by disease in 2000–01. Disease and injury groups are defined according to the first 
Australian Burden of Disease (BoD) study (AIHW: Mathers et al. 1999).  
These disease expenditure estimates allocate around 86% of recurrent health 
expenditure by disease, or $49.2 billion in total. Expenditure not allocated by disease 
includes expenditure on community and public health services, health 
administration, the transport of patients, and health aids and appliances.  
Main results 
The seven disease groups that account for the greatest health expenditure in 
Australia are: 
• Cardiovascular diseases—$5.4 billion (11.0% of total allocated health 
expenditure) 
• Nervous system disorders —$4.9 billion (9.9%)  
• Musculoskeletal diseases—$4.7 billion (9.6%) 
• Injuries—$4.1 billion (8.3%) 
• Respiratory diseases—$3.5 billion (7.2%) 
• Oral health—$3.4 billion (6.9%) 
• Mental disorders $3.0 billion (6.1%). 
These seven conditions together account for $29 billion, or 59% of allocated health 
expenditure. 
For 2000–01 cardiovascular disease was the most expensive group ($5.4 billion), and 
also accounted for 38% of deaths. 
Nervous system disorders was the second most expensive group ($4.9 billion) and 
has increased significantly since 1993–94, mostly because of a large increase in 
expenditure for people with Alzheimer’s disease and other dementias in aged care 
homes.  
Expenditure in the National Health Priority Areas 
The National Health Priority Areas (NHPAs) are cardiovascular health, cancer 
control, injury prevention and control, mental health, musculoskeletal conditions, 
diabetes mellitus, and asthma. Together, they account for $21.4 billion, or 43.5% of 
allocated health system expenditure.  
Four of the seven NHPAs rank within the top seven conditions listed above—
cardiovascular disease, musculoskeletal diseases, mental disorders and injury. The 
fifth, neoplasms, ranks ninth ($2.8 billion, or 5.6% of allocated expenditure); and the 
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sixth, diabetes, ranks fifteenth ($0.8 billion or 1.7% of allocated expenditure). Asthma 
is the seventh NHPA. It is contained within the respiratory diseases group and 
accounts for $0.6 billion, or 1.2% of allocated health expenditure.  
Health expenditure by age and sex  
Health system expenditures allocated by disease are 26% higher for females than for 
males—$27.4 billion compared with $21.8 billion.  Expenditure per person is $2,821 
for females which is 24% higher than the $2,277 for males. When maternal conditions 
are excluded, expenditure per person for females is 18% higher than for males. 
Expenditure per person is higher for females than males for disease groups such as 
the nervous system, musculoskeletal conditions and oral health.  It is higher for 
males for the cardiovascular, cancer and injury groups.  
Health expenditure per person is $2,426 on average per year for males aged 0 to 4 
years. It then decreases to $1,146 for boys aged 5 to 14 years and from there increases 
with age to $10,719 for men aged 75 years and over.  For females, the pattern is the 
same for children, but in adulthood expenditure peaks in the 25–34 years age group, 
reflecting child-bearing expenditure; it then declines for the age range 35 to 44 years 
and from there increases steadily with age to $11,346 per year for women aged 75 
years or over.  
Changes in health expenditure by disease, 1993–94 to 2000–01 
Between 1993–94 and 2000–01 the growth in inflation-adjusted expenditure which 
could be allocated to disease was $13.2 billion—which represents growth of 37%.  
This was an average annual increase of 4.6%.  
Areas which showed above-average growth during the period were oral health 
(50%), nervous system disorders (45%) and digestive system diseases (38%).  The 
high growth in nervous system disorders expenditure was the result of the large 
increase in expenditure on care for people with dementia in aged care homes.   
Areas which showed below-average growth were respiratory diseases (22%), 
cardiovascular disease (26%), neoplasms (31%) and mental disorders (32%). The 
lower growth for mental disorders was due to the fact that these disease expenditure 
estimates do not include expenditure on community mental health services.  Growth 
was 43% when this was included. 
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1 Introduction 
This publication presents estimates of health expenditure on disease and injury in 
Australia in 2000–01, classified by disease or injury group, age and sex. The estimates 
are available by area of expenditure—hospitals, high-level residential aged care, 
medical services, other professional services, pharmaceuticals and research.  
The 2000–01 disease expenditure estimates were based on the 176 disease and injury 
conditions used in the first Australian burden of disease study (AIHW: Mathers et al. 
1999), with the inclusion of some additional sub-categories. This report aggregates 
these conditions into the 19 broad disease groups used by the burden of disease 
study. Disease expenditure estimates are also presented for selected conditions in the 
seven National Health Priority Areas and by age and sex.  
These disease expenditure estimates allocate 86% of total recurrent health 
expenditure in 2000–01, or just under $49.2 billion. The expenditure not allocated by 
disease is capital expenditures, and expenditure on community health, public health 
programs, health administration and health aids and appliances.  
The disease expenditure database is comprehensive and expenditure estimates by 
source of funds (i.e. commonwealth, state or private) for each area of expenditure are 
able to be produced. For some areas of expenditure, state and territory estimates will 
be available. Utilisation measures such as bed days, separations, number of medical 
encounters and services and pharmaceutical scripts can also be estimated.  
1.1 Use and interpretation of expenditure estimates 
Disease-specific expenditure estimates provide a useful perspective on the utilisation 
and costs of health services in Australia, as well as a reference source for planners 
and researchers interested in the costs and utilisation patterns for a particular disease 
group. The estimates presented in this report are derived in a consistent framework, 
but it is important that their interpretation and limitations be clearly understood. The 
most important points to note are: 
• Existing expenditure on a disease, no matter how large or small, does not in itself 
give an indication of the loss of health due to that disease or the priority for 
intervention or need for additional health services expenditure. Resource 
allocation decisions require information not only on average costs and outcomes 
but also on the marginal costs and marginal outcomes associated with the 
specific interventions under consideration. 
• Care should be taken when interpreting expenditure associated with disease 
treatment as an estimate of the savings that would result from prevention of 
disease. Conversion of the opportunity cost of resources being devoted to disease 
treatment, or the benefits forgone, into expenditure savings involves a number of 
additional considerations (see, for example, AIHW: Mathers et al. 1998b). 
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• Although the expenditure estimates reported here provide a broad picture of use 
of health system resources classified by disease group, they should be interpreted 
with caution for specific diseases because, although the methodology yields 
consistency, good coverage and totals that add up to known expenditures, it is 
not as sensitive or accurate for any specific disease as a detailed analysis of actual 
costs incurred by patients with that disease. 
Monetary expenditure on health services by itself tells us little about what is 
happening in the health system or about priorities for funding or interventions. If, 
however, these expenditures can be linked to output and outcome measures (such as 
number of hospital admissions and changes in health status) the expenditure 
information becomes more meaningful, especially if dissected by disease categories.  
Disease expenditure estimates cannot provide a comprehensive assessment of the 
impact of disease on the welfare of society. Nevertheless, they can be useful 
indicators of the economic burden individual diseases place on a society and can 
help identify how health resources are currently allocated to different diseases and 
population subgroups. 
1.2 Background 
The first detailed Australian study of expenditure across disease and injury groups 
was published in 1998 and referred to the year 1993–94 (AIHW: Mathers et al. 1998b). 
This study classified disease and injury according to the major chapter groupings of 
the International Classification of Diseases Ninth Revision (ICD-9).  
The 1993–94 disease expenditure estimates were for the treatment costs of disease 
(and some prevention costs) by area of expenditure (i.e. hospitals, nursing homes, 
medical services, other professional services, and pharmaceuticals) and by age and 
sex groups (AIHW: Mathers et al. 1998a). 
1.3 Methodology 
The expenditure on disease as presented in this report is an example of a satellite 
national account.  Satellite accounts enable the linkage of non-monetary data sources 
and analysis to the monetary accounting system. In health, such accounts were first 
proposed by Stone in 1975 (United Nations 1975). The UN System of National 
Accounts 1993 introduced the concept of satellite accounts as a way of going beyond 
the rigidities of the National Accounts structure to provide a focus on data which is 
of relevance to specific policy areas (CEC, IMF, OECD, UN & WB 1993).  
To ensure consistency across the disease expenditure project and the associated 
burden of disease project, the disease groups used in the 2000–01 disease expenditure 
estimates were based on the 176 diseases that were published in the Australian 
burden of disease study (AIHW: Mathers et al. 1999). Extra categories were added to 
provide a more comprehensive list of diseases, and, as in 1993–94, the two categories 
of  ‘Symptoms, signs and ill-defined conditions’ and ‘Other contact with health 
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services’ were included to cover those health service expenditures which cannot be 
allocated by disease. Inclusion of these two categories allows for the allocation of all 
the ICD-10 codes.  
The 2000–01 estimates were derived using a methodology which is consistent with 
that used for the 1993–94 estimates, in order to allow better comparisons between the 
estimates for the two years. The use of the burden of disease study categories, 
however, means that not all the expenditure estimates as published are directly 
comparable. In particular for the 2000–01 estimates: 
• In the burden of disease categorisation, dementia (Part of ICD-10 chapter V: 
Mental and behavioural disorders) is included with Alzheimer’s disease (Part of  
ICD-10 chapter VI: Diseases of the nervous system). For these expenditure 
estimates, therefore, all dementia and Alzheimer’s disease expenditure is in the 
burden of disease chapter K: Nervous system and sense organ disorders. 
• Diabetes is presented separately from the endocrine, nutritional & metabolic 
disorders group. 
• Oral health is presented separately from the digestive system disorders group. 
When comparisons of 2000–01 and 1993–94 are made later in this report, adjustments 
have been made to allow where possible for these differences, but comparisons made 
using published 1993–94 results will not be valid.  
The full set of ICD-9 codes used in the burden of disease categories is in Annex 
Table A of The Burden of Disease and Injury in Australia (AIHW: Mathers et al. 1999). 
Since the 1993–94 study, nursing homes and hostels have been integrated into a 
single residential aged care system. The ‘nursing home’ portion of 2000–01 
residential aged care services expenditure is estimated on the basis of residents’ level 
of dependency, with expenditure on high-dependency residents (RCS categories 1–4) 
taken as approximating expenditure on nursing homes.  
Disease expenditure estimates for 2000–01 are available by the following areas of 
expenditure: hospitals, aged care homes, out-of-hospital medical services, 
pharmaceuticals, other professional services, dental, and research. A detailed 
analysis was undertaken for admitted hospital patients, aged care homes, out-of-
hospital medical services, and pharmaceuticals requiring a prescription (72% of 
allocated expenditure). For other areas of expenditure, estimates were made by 
adjusting the 1993–94 estimates for changes in the age and sex structure of the 
population and then multiplying these by a factor that ensured they add to the 
known total 2000–01 expenditure for that area.  
Areas of health expenditure 
Hospital: admitted patients 
The proportions of total public acute hospital expenditure which relate to admitted 
patients are estimated using the admitted patient fractions estimated by each state 
and territory and published in Australian Hospital Statistics 2001–02 (AIHW 2003a). 
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Private hospital expenditure data are derived from the Australian Bureau of Statistics 
Private Health Establishments Survey. 
The hospital morbidity expenditure method estimates acute hospital admitted 
patient costs by apportioning the total admitted patient expenditure to individual 
episodes of hospitalisation with an adjustment for the resource intensity of treatment 
for the specific episode (using the Diagnostic Related Groups, or DRGs) and the 
length of stay. The length of stay adjustment is made in such a way as to reflect the 
fact that some costs are proportional to length of stay (e.g. ward costs and meals), 
whereas others are independent of length of stay (e.g. theatre costs).  The subdivision 
of episode costs into these cost ‘buckets’ was made using National Hospital Costs 
Data Collection data. 
An adjustment is also made for the actual hospital where the treatment is provided. 
The standard DRG method for estimating costs uses state DRG weights, and so 
assumes that the hospital has the same average costliness as the average for the state.  
The establishment’s database contains the actual cost of treating admitted patients at 
each hospital, so these data are used to scale up or down the estimate that comes 
from using state DRG weights.  
For sub-acute and non-acute patients, where there are no DRG weights, the most 
recent data on costs comes from the July to December 1996 sub-acute and non-acute 
patient (SNAP) study (Eagar et al. 1997). Per diem costs were applied and inflated to 
2000–01 estimates using the implicit price deflator for final government consumption 
expenditure on hospital and nursing home care (AIHW 2002). 
Estimates of expenditure on medical services for private patients in hospitals are 
included in admitted patient hospital costs.  Expenditure for private medical services 
in 2000–01 was $1,822 million. This estimate comes from Health Insurance 
Commission data on the fee charged by private medical practitioners for in-hospital 
services. Sometimes specialists accept a discounted amount as full payment for the 
services, so the fee-charged data will be a slight overestimate of actual expenditure 
for private medical services in hospitals.  
Hospital: non-admitted patients 
Total expenditure for non-admitted patients comes from Australian Hospital Statistics 
2001–02 (AIHW 2003a). The figure was broken down by disease by adjusting the 
1993–94 non-admitted patient disease expenditure pattern for demographic changes. 
These numbers are therefore, preliminary. 
Aged care homes 
Since the 1993–94 disease costing study was undertaken, nursing homes and hostels 
have been integrated into a single residential aged care system. People receiving 
residential aged care are categorised according to the level of care they receive. Each 
resident is categorised into one of eight care categories on admission and this 
categorisation is periodically reviewed. The ‘nursing home’ portion of residential 
aged care services expenditure is estimated on the basis of this level of care. Levels 1 
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to 4 roughly relate to residents with high levels of dependency and are 
approximately equivalent to the services delivered by nursing homes in the past.  
Expenditure for residents categorised to RCS levels 1 to 4 in aged care homes comes 
from Health Expenditure Australia 2001–02 (AIHW 2003b). It is allocated to disease 
based on data from the Australian Bureau of Statistics 2003 Survey of Disability, 
Ageing and Carers which asks staff in aged care homes which health condition  
causes the most problems for residents.  
Out-of-hospital medical services 
Data from the general practitioners survey, Bettering the Evaluation and Care of 
Health, or BEACH, was used to allocate private medical services provided by both 
GPs and specialists. The International Classification of Primary Care Version 2 codes 
used in BEACH were mapped to the disease costing groups to enable medical 
services expenditure to be allocated by disease. Expenditures for ‘Unreferred 
attendances’, ‘Imaging’ and ‘Pathology’ were allocated to disease on the basis of GP 
encounters, while expenditure for ‘Other medical services’ was allocated to disease 
on the basis of the referral pattern in BEACH. Expenditure for ‘Optometry’ was 
allocated to the disease group ‘Disorders of refraction’ under chapter K: Nervous 
system and sense organ disorders. Allocation of GP costs where there are multiple 
presenting conditions in the GP encounter was done on a pro-rata basis.  
In-hospital medical expenditure for private patients is not included under medical 
services, but is allocated as part of admitted patient expenditure.  (Health Expenditure 
Australia 2001–02 (AIHW 2003b) includes this in-hospital medical expenditure in the 
category ‘medical services’). 
Pharmaceuticals 
Prescription drugs 
The Department of Health and Ageing provided detailed costing data for 
pharmaceuticals issued under the Pharmaceutical Benefits Scheme and the 
Department of Veterans’ Affairs Repatriation Pharmaceutical Benefits Scheme. It also 
provided volume data for private prescriptions and under-copayment drugs. These 
data originally came from a Pharmacy Guild survey and were adjusted by the 
Department to represent volume figures for all of Australia. Costing figures were 
applied to these prescription drugs, to obtain a total expenditure figure for each 
prescription drug. Prescription drugs were coded by the fifth edition of the 
Anatomical Therapeutic Chemical classification a system developed by the World 
Health Organization for classifying therapeutic drugs (WHO Collaborating Centre 
for Drug Statistics Methodology 2002). The codes were mapped to codes for 
prescription drugs used in the BEACH survey. As a result, data from BEACH were 
used to allocate expenditure on prescription drugs to each disease group, based on 
the medical problem in the GP encounter that related to the prescribing of the 
particular drug. An assumption was made that the pattern of diseases relating to 
each type of prescription drug is the same when prescribed by a GP and by a 
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specialist. This assumption was applied because there are no data that permit 
allocation of specialist-written prescriptions to diseases.  
Pharmaceuticals that are dispensed in hospitals are included in the estimates of 
hospital costs. 
Over-the-counter drugs 
Health Expenditure Australia 2001–02 (AIHW 2003b) separates expenditure on 
pharmaceuticals into ‘Benefit paid pharmaceuticals’ and ‘All other pharmaceuticals’. 
‘All other pharmaceuticals’ include over-the-counter drugs but also pharmaceuticals 
for which a script is required such as private prescriptions and under-copayment 
drugs. The estimates in this report separate pharmaceuticals for which a script is 
required from over-the-counter drugs. Therefore, in order to calculate the 
expenditure on over-the-counter drugs, expenditure on private prescriptions and 
under-copayment drugs was subtracted from ‘All other pharmaceuticals’.  
Expenditure on over-the-counter drugs in 2000–01 by disease is based on a revision 
to the 1993–94 disease costing estimates that allows for demographic change, and 
increases in the expenditure in this area.   
Other professional services 
Total expenditure on ‘Other professional services’ was obtained from Health 
Expenditure Australia 2001–02 (AIHW 2003b) and was allocated to disease by adjusting 
the 1993–94 disease figures for demographic change. 2000–01 disease expenditure 
estimates for ‘Other professional services’ are therefore approximations and should 
be used with caution.  
Dental services 
Total expenditure on ‘Dental services’ was obtained from Health Expenditure Australia 
2001–02 (AIHW 2003b) and was allocated to the oral health category. The age and sex 
estimates for 2000–01 were obtained using the 1993–94 age-sex expenditure 
distribution against the 2000–01 age-sex population structure, and are therefore 
approximate.  
Research 
Total expenditure on ‘Research’ was obtained from Health Expenditure Australia 
2001–02 (AIHW 2003b) and was allocated to disease using data from the latest 
Australian Bureau of Statistics research and experimental development surveys. 
Most of the research data is classified at a fairly high level, but it does give a valid 
picture of the distribution of research expenditure at the chapter level. Within a 
chapter, research is allocated in proportion to the distribution of all other 
expenditure by disease within that chapter.  
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2 Results 
2.1 Total expenditure 
Table 2 shows health expenditure in Australia in 2000–01, summarised at the broad 
disease group level. This expenditure includes expenditure funded by the 
Commonwealth and State governments, by private health insurance and by 
individuals and households. These disease expenditure estimates allocate 86% of 
total recurrent health expenditure in 2000–01, or just under $49.2 billion. Expenditure 
not allocated by disease is capital expenditure and expenditure on community health 
services, public health programs, patient transport, health administration, and health 
aids and appliances (Table 1).  Welfare expenditures such as the Home and 
Community Care program and low-level care in aged care homes are not included.  
Table 1: Total health expenditure in Australia, 1993–94 and 2000–01 ($ million) 
Expenditure 1993–94(a) 
% of total 
recurrent 
expenditure 2000–01 
% of total 
recurrent 
expenditure 
Allocated recurrent expenditure 29,999 87.9 49,174 85.8 
Unallocated recurrent expenditure     
Ambulance 484 1.4 994 1.7 
Aids and appliances 770 2.3 2,108 3.7 
Community and public health 1,558 4.6 3,095 5.4 
Administration 1,099 3.2 1,942 3.4 
Other non-institutional not 
elsewhere classified(b) 109 0.3 
 
 
Other institutional not elsewhere 
classified(c) 121 0.4 
 
 
Total unallocated  3,956 11.6 8,122 14.2 
Total recurrent expenditure 34,141 100.0 57,297 100.0 
Capital expenditure/outlays(d) 1,852  2,631  
Capital consumption(d) 523  970  
Total health expenditure 36,516  60,897  
(a) The results for 1993–94 have been adjusted to align with the 2000–01 classifications for allocated and non-allocated areas of expenditure. 
(b) ‘Other non-institutional not elsewhere classified’ is included in ‘Community and public health’ for 2000–01. 
(c) ‘Other institutional not elsewhere classified’ is included in ‘Allocated recurrent expenditure’ for 2000–01. 
(d) Capital expenditure and capital consumption for 1993–94 is from AIHW (2002). 
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The seven disease groups that account for the greatest health expenditure in 
Australia (Table 3) are: 
• Cardiovascular diseases—$5.4 billion (11.0% of total allocated health 
expenditure) 
• Nervous system disorders —$4.9 billion (9.9%)  
• Musculoskeletal diseases—$4.7 billion (9.6%) 
• Injuries—$4.1 billion (8.3%) 
• Respiratory diseases—$3.5 billion (7.2%) 
• Oral health—$3.4 billion (6.9%) 
• Mental disorders $3.0 billion (6.1%). 
These seven conditions together account for $29 billion, or 59% of allocated health 
expenditure. 
In 1993–94 these seven disease groups also accounted for the most health 
expenditure in Australia, but the proportions of expenditure were somewhat 
different. The top seven were cardiovascular diseases (12%), musculoskeletal 
diseases (10%), injuries (8%), respiratory diseases (8%), nervous system disorders 
(7.5%), mental disorders (6.4%) and oral health (6.2%) (calculated from AIHW: 
Mathers et al. 1998b).   
The fall in the proportion of expenditure on mental disorders from 6.4% in 1993–94 to 
6.1% in 2000–01 occurs because community mental health expenditure ($340m in 
1993–94 and $842m in 2000–01) is not included in these disease expenditure 
estimates. This increase represented the change in focus in mental health from 
hospital care to community care.  When adjustment is made for this, mental 
disorders expenditure increased from 7.5% of allocated health expenditure in 1993–
94 to 7.9% in 2000–01.  
For 2000–01, cardiovascular disease was the most expensive group ($5,393 million), 
and also accounted for a high proportion of deaths—38% (Table 3). 
Nervous system disorders was the second most expensive group and has increased 
significantly since 1993–94, mostly because of a large increase in expenditure for 
people with Alzheimer’s disease and other dementias in aged care homes. 49% of 
expenditures for high-level care in aged care homes was estimated to be due to 
Alzheimer’s and other dementias in 2000–01(Table 2).    
Cancer ranks ninth in terms of direct costs, but is the second highest contributor to 
deaths (37,615 deaths, or 29% of all deaths).   
It is interesting to note that musculoskeletal diseases and injuries, which include 
many long-term chronic disorders with relatively low fatality rates but high levels of 
disability and reduced functionality, rank highly in the direct cost estimates. 
Nervous system disorders, mental disorders, musculoskeletal diseases and injuries 
rank highly in terms of costs ($16.7 billion, or 34% of allocated health system costs), 
but cause only 12% of deaths.  
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As the fifth most expensive disease group, respiratory diseases are the third-largest 
cause of death for 2000–01, about two-thirds of which are due to pneumonia and 
chronic obstructive pulmonary disease (COPD).  
Ranked sixth is oral health, with 7% of expenditure but, of course, very few deaths.   
For all diseases, 45% of direct health system costs allocated by disease are within the 
hospital sector (which includes admitted patient and non-admitted patient services 
in public and private hospitals), 17% of costs are for out-of-hospital medical services, 
16% for pharmaceuticals, 8% for the high-care component of aged care homes, 6% for 
dental services and 5% for other health professionals (Table 3). 
It should be noted that expenditure in aged care homes is not entirely for health 
purposes. Much of this expenditure is on food, lodging and other necessities of daily 
life and occurs regardless of the disease a person has. Thus only a portion of aged 
care home expenditure should be considered to be a consequence of disease.  
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Table 2: Allocated recurrent expenditure in Australia, by broad disease group, 2000–01 ($ million) 
 Hospitals    Pharmaceuticals    
Disease group 
Admitted 
patients(a) 
Non-
admitted 
services Total 
Aged care 
homes(b) 
Out-of-
hospital 
medical 
services 
Other 
professional 
services(c)(f) 
Prescription
(d) 
Over-the-
counter(c)(e) Total Dental Research 
Total 
expenditure 
allocated 
by disease 
Infectious & parasitic 340 138 478 8 367 27 192 41 233 0 139 1,251 
Respiratory 1,101 336 1,437 88 821 64 592 495 1,087 0 35 3,533 
Maternal conditions 1,096 81 1,178 na 110 10 3 7 10 0 11 1,318 
Neonatal causes 334 na 334 na 13 0 1 0 1 0 11 359 
Neoplasms 1,716 272 1,988 37 273 24 210 16 226 0 215 2,764 
Diabetes mellitus 231 58 289 38 187 36 238 13 251 0 35 836 
Endocrine, nutritional 
and metabolic 287 108 396 14 344 64 635 51 686 0 67 1,571 
Mental disorders(g)   1,049 147 1,196 366 589 144 550 65 615 0 109 3,018 
Nervous system 
disorders 811 304 1,115 2,168 523 410 363 75 438 0 204 4,858 
Alzheimer’s and 
other dementias 174 na 175 1,902 20 9 33 1 33 0 112 2,251 
Other nervous 
system 637 na 939 267 503 401 330 74 404 0 92 2,606 
Cardiovascular 2,235  298 2,533 526 716 78 1,134 253 1,386 0 153 5,393  
Digestive system 1,382  190 1,571 34 359 204 484 138 622 0 31 2,821  
Genitourinary 1,071  246 1,317 14 458 31 189 59 248 0 13 2,081  
Skin diseases 307  255 562 13 350 103 134 218 351 0 13 1,392  
Musculoskeletal 1,286  542 1,828 482 908 760 480 212 691 0 55 4,725  
                  (continued) 
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Table 2 (continued): Allocated recurrent expenditure in Australia by broad disease group, 2000–01 ($ million) 
 Hospitals    Pharmaceuticals    
Disease group 
Admitted 
patients(a) 
Non-
admitted 
services Total 
Aged care 
homes(b) 
Out-of-
hospital 
medical 
services 
Other 
professional 
services(c)(f) 
Prescription
(d) 
Over-the-
counter(c)(e) Total Dental Research 
Total 
expenditure 
allocated 
by disease 
Congenital 
anomalies 158  0 158 6 21 1 2 0 2 0 37 224  
Oral health 133  56 189 0 15 26 9 27 36 3,084 27 3,376  
Injuries 1,644  1,186 2,830 105 647 284 114 76 190 0 6 4,061  
Signs, symptoms, ill-
defined conditions 
and other contact 
with health system(h) 2,165  468 2,633 0 1,753 174 567 444 1,011 0 21 5,593  
Total 17,347  4,683 22,030 3,899 8,454 2,440  5,896 2,189 8,085 3,084 1,182 49,174  
(a)  Includes a preliminary estimate of private medical services provided in hospital.           
(b)  Includes expenditure on residents that require and receive a level of care that falls within one of the four highest levels in residential aged care services.       
(c)  Based on preliminary AIHW estimates.           
(d)  Includes all pharmaceuticals for which a prescription is needed, including private prescriptions and under-copayment prescriptions.        
(e)    Includes over-the-counter medicaments such as vitamins and minerals, patent medicines, first aid and wound care products, analgesics, feminine hygiene products, cold sore preparations, and a number of 
complementary health products that are sold in both pharmacies and other retail outlets.    
(f)  Includes services delivered outside of hospitals by paramedical professionals such as physiotherapists, chiropractors, occupational therapists, audiologists, speech therapists, hydropaths, podiatrists, therapeutic and 
clinical massage therapists, clinical psychologists, dietitians and osteopaths. 
(g)  Does not include expenditure on community mental health services (see p. 10). 
(h)   ‘Signs, symptoms and ill-defined conditions’ includes diagnostic and other services for signs, symptoms and ill-defined conditions where the cause of the problem is unknown. ‘Other contact with the health system’ 
includes fertility control, reproduction and development; elective plastic surgery; general prevention, screening and health examination; and treatment and aftercare for unspecified disease. 
 14 
 
 
Table 3: Diseases and injury by burden of disease chapter: health system costs by health sector, 2000–01 ($ million) and number of deaths, 2001 
Burden of disease chapter Hospitals(a) 
Aged care 
homes(b) 
Out-of-
hospital 
medical 
services 
Dental(d) and 
other 
professional 
services(c) (e) 
Total 
pharmaceuticals 
(f) Research 
Total 
expenditure 
allocated by 
disease 
% of total 
allocated 
expenditure 
Number 
of 
deaths 
% of 
total 
deaths 
Cardiovascular 2,533 526 716 78 1,386 153 5,393 11.0 49,172 38.3 
Nervous system 1,115 2,168 523 410 438 204 4,858 9.9 6,260 4.9 
Musculoskeletal 1,828 482 908 760 691 55 4,725 9.6 899 0.7 
Injuries 2,830 105 647 284 190 6 4,061 8.3 7,483 5.8 
Respiratory 1,437 88 821 64 1,087 35 3,533 7.2 10,682 8.3 
Oral health 189 0 15 3,110 36 27 3,376 6.9 12 0.0 
Mental disorders(g) 1,196 366 589 144 615 109 3,018 6.1 939 0.7 
Digestive system 1,571 34 359 204 622 31 2,821 5.7 4,107 3.2 
Neoplasms 1,988 37 273 24 226 215 2,764 5.6 37,615 29.3 
Genitourinary 1,317 14 458 31 248 13 2,081 4.2 3,168 2.5 
Endocrine, nutritional & metabolic 396 14 344 64 686 67 1,571 3.2 1,651 1.3 
Skin diseases 562 13 350 103 351 13 1,392 2.8 266 0.2 
Maternal conditions 1,178 0 110 10 10 11 1,318 2.7 12 0.0 
Infectious & parasitic 478 8 367 27 233 139 1,251 2.5 1,746 1.4 
(continued) 
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Table 3 (continued): Diseases and injury by burden of disease chapter: health system costs by health sector, 2000–01 ($ million), and number of deaths, 
2001  
Burden of disease chapter Hospitals(a) 
Aged care 
homes(b) 
Out-of-
hospital 
medical 
services 
Dental(d) and 
other 
professional 
services(c)(e) 
Total 
pharmaceuticals 
(f) Research 
Total 
expenditure 
allocated by 
disease 
% of total 
allocated 
expenditure 
Number 
of 
deaths 
% of 
total 
deaths 
Diabetes mellitus 289 38 187 36 251 35 836 1.7 3,089 2.4 
Neonatal causes 334 0 13 0 1 11 359 0.7 690 0.5 
Congenital anomalies 158 6 21 1 2 37 224 0.5 623 0.5 
Signs, symptoms, ill-defined 
conditions and other contact with 
the health system(h) 2,633 0 1,753 174 1,011 21 5,593 11.4 125 0.1 
Total 22,030 3,899 8,454 5,524 8,085 1,182 49,174 100.0 128,540 100.0 
As percent of  total 44.8 7.9 17.2 11.2 16.4 2.4 100.0      
(a)  Public and private acute hospitals and psychiatric hospitals. Includes a preliminary estimate of private medical services provided in hospital.  
(b) Includes expenditure on residents that require and receive a level of care that falls within one of the four highest levels in residential aged care services. 
(c)  Based on preliminary AIHW estimates.        
(d)  Expenditure on dental services was $3,084 million and is all included in the ‘Oral health' category.      
(e)  Includes services delivered outside of hospitals by paramedical professionals such as physiotherapists, chiropractors, occupational therapists, audiologists, speech therapists, hydropaths, podiatrists, therapeutic and 
clinical massage therapists, clinical psychologists, dietitians and osteopaths.        
(f)  Includes all pharmaceuticals for which a prescription is needed, including private prescriptions and under-copayment prescriptions, and includes over-the-counter medicaments such as vitamins and minerals, patent 
medicines, first aid and wound care products, analgesics, feminine hygiene products, cold sore preparations, and a number of complementary health products that are sold in both pharmacies and other retail outlets.  
(g)  Does not include expenditure on community mental health services (see p. 10). 
(h)  ‘Signs, symptoms and ill-defined conditions’ includes diagnostic and other services for signs, symptoms and ill-defined conditions where the cause of the problem is unknown. ‘Other contact with the health system’ 
includes fertility control, reproduction and development; elective plastic surgery; general prevention, screening and health examination; and treatment and aftercare for unspecified disease. 
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2.2 Expenditure on National Health Priority Area 
conditions 
The National Health Priority Areas (NHPA) initiative is a collaborative effort 
involving the Australian Government and state and territory governments. It seeks 
to focus public attention and health policy on those areas that are considered to 
contribute significantly to the burden of disease in Australia, and for which there is 
potential for health gain. The NHPAs agreed by the Australian Health Ministers are 
cardiovascular health, cancer control, injury prevention and control, mental health, 
musculoskeletal conditions, diabetes mellitus and asthma. Table 4 shows 
expenditure on each of these areas in 2000–01. Together, the NHPAs account for 
$21.4 billion, or 43.5% of allocated health system expenditure.  
Four of the seven NHPAs rank within the top seven conditions listed in Section 2.1—
cardiovascular disease, musculoskeletal diseases, mental disorders and injury. The 
fifth, neoplasms, ranks ninth ($2.76 billion, or 5.6% of allocated expenditure); and the 
sixth, diabetes, ranks fifteenth ($0.8 billion or 1.7% of allocated expenditure). 
Diabetes also is a cause of other diseases such as cardiovascular and renal diseases, 
so total health expenditure attributable to diabetes is greater than $0.8 billion. 
Asthma is the seventh NHPA. It is contained within the respiratory diseases group 
and accounts for $0.6 billion, or 1.2% of allocated health expenditure (Figure 1).  
 
  
Figure 1: Health system costs for NHPAs, Australia 2000–01 
 
Cardiovascular (11.0%)
Musculoskeletal (9.6%)
Injuries (8.3%) 
Asthma (1.3%) 
Neoplasms (5.6%)
Mental disorders (6.1%)
Diabetes mellitus (1.7%)
All other causes (56.5%)
 17 
 
Table 4: Allocated recurrent health expenditure on National Health Priority Areas, 2000–01 ($ million) 
 Hospital Pharmaceuticals 
Disease group 
Admitted 
patients 
(a) 
Non-admitted 
services Total 
Aged 
care 
homes 
(b) 
Out-of-
hospital 
medical 
services 
Other 
professional 
services(c)(f) 
Prescription 
(d) 
Over-the-
counter 
(c)(e) Total Research 
Total 
expenditure 
allocated by 
disease 
All cardiovascular diseases  2,235 298 2,533 526 716 78 1,134 253 1,386 153 5,393  
Ischaemic heart disease 1,083 37 1,120 25 106 11 166 17 183 44 1,488 
Stroke 362 30 392 442 28 10 24 6 30 20 922 
Other conditions 789 232 1,021 59 583 57 944 230 1,173 90 2,984 
All musculoskeletal conditions  1,286 542 1,828 482 908 760 480 212 691 55 4,725 
Arthritis 571 104 674 325 167 81 134 63 197 17 1,461 
Other conditions  716 438 1,153 157 741 680 345 149 494 38 3,264 
Injuries 1,644 1,186 2,830 105 647 284 114 76 190 6 4,061 
Neoplasms 1,716 272 1,988 37 273 24 210 16 226 215 2,764 
All mental disorders(g)  1,049 147 1,196 366 589 144 550 65 615 109 3,018 
Depression 236 24 260 89 330 22 292 10 302 38 1,042 
Other conditions  812 123 935 277 259 122 258 55 312 71 1,976 
Diabetes mellitus 231 58 289 38 187 36 238 13 251 35 836 
Asthma 107 72 179 16 103 21 216 74 290 6 615 
All NHPA 8,268 2,574 10,842 1,570 3,423 1,347 2,942 708 3,650 580 21,412 
(a)  Includes a preliminary estimate of private medical services provided in hospital.           
(b)  Includes expenditure on residents that require and receive a level of care that falls within one of the four highest levels in residential aged care services.       
(c)  Based on preliminary AIHW estimates.           
(d)  Includes all pharmaceuticals for which a prescription is needed, including private prescriptions and under-copayment prescriptions.       
(e)      Includes over-the-counter medicaments such as vitamins and minerals, patent medicines, first aid and wound care products, analgesics, feminine hygiene products, cold sore preparations, and a number of 
complementary health products that are sold in both pharmacies and other retail outlets.  
(f)  Includes services delivered outside of hospitals by paramedical professionals such as physiotherapists, chiropractors, occupational therapists, audiologists, speech therapists, hydropaths, podiatrists, therapeutic and 
clinical massage therapists, clinical psychologists, dietitians and osteopaths. 
(g) Does not include expenditure on community mental health services (see p. 10).      
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Table 5: NHPA expenditure as a proportion of allocated health expenditure, 2000–01  
  Disease expenditure ($ 
million) 
Each NHPA as per 
cent of total 
Per cent of total 
NHPA cost 
Cardiovascular 5,393 11.0 25.2 
Musculoskeletal  4,725 9.6 22.1 
Injuries 4,061 8.3 19.0 
Asthma  615 1.2 2.9 
Neoplasms  2,764 5.6 12.9 
Mental disorders (a) 3,018 6.1 14.1 
Diabetes mellitus  836 1.7 3.9 
Total by NHPAs 21,412 43.5 100.0 
All other causes  27,762 56.5  
(a) Does not include expenditure on community mental health services (see p. 10). 
 
Table 6 shows the cost components for each NHPA. Most health system expenditure 
for the seven NHPAs was in the hospital and aged care home sector (58% of all 
NHPA expenditure). Expenditure on NHPAs for the medical and other health 
professional sector (22.3%), which includes consultations with GPs and specialists, 
pathology and diagnostic imaging services, and other health professionals was about 
the same as that for all diseases (22.2%) (Table 6). The pharmaceutical cost for 
NHPAs amounted to 17.0% of NHPA expenditure, a proportion slightly higher than 
that of total pharmaceutical expenditure for the entire health system (16.4%). 
 
Cardiovascular
Musculoskeletal
Injuries
Asthma
Mental disorders
Neoplasms
Diabetes mellitus
0 1,000 2,000 3,000 4,000 5,000 6,000
$ million
Hospital and aged-care 
homes
Medical and other health 
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Research
 
Figure 2: Total cost of disease, by health sector for NHPA, Australia, 2000–01 
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Table 6: Diseases and injuries in NHPAs: allocated health system costs, by health sector, Australia, 
2000–01 ($ million)    
NHPA  
Hospital and 
aged care 
homes(a) 
Medical and 
other health 
professionals(b) Pharmaceuticals Research(c) All sectors 
Cardiovascular 3,059 794 1,386 153  5,393 
Musculoskeletal 2,310 1,669 691 55  4,725 
Injuries 2,935 931 190 6  4,061 
Asthma(c) 196 123 290 6  615 
Mental disorders(d) 1,561 733 615 109  3,018 
Neoplasms 2,025 297 226 215  2,764 
Diabetes mellitus 327 223 251 35  836 
Total for NHPAs 12,412 4,770 3,650 580  21,412 
% of NHPAs sector total by total 
cost of NHPAs 58.0 22.3 17.0 2.7  100.0 
Total for all diseases 22,030 10,894 8,085 8,165  49,174 
% of NHPAs of all diseases, by 
sector 56.3 43.8 45.1 7.1  43.5 
% of all diseases by total health 
system cost, by sector   44.8 22.2 16.4 16.6  100.0 
(a) Public and private acute hospitals, psychiatric hospitals and aged care homes.   
(b) Includes out-of-hospital medical services, dental and other health professional services.  
(c) Part of Respiratory disease category.    
(d) Does not include expenditure on community mental health services (see p. 10). 
 
Different illnesses require different treatment modes (Figure 3). For cardiovascular 
diseases, injuries, neoplasms and mental disorders, expenditure in hospitals and 
aged care homes account for a relatively high proportion of total expenditure, 
reflecting these conditions’ demand for labour-intensive health services. 
Pharmaceutical costs for asthma, diabetes, cardiovascular conditions and mental 
disorders constitute a significant part of the total cost of treating these diseases.  Such 
expenditures reflect not only the chronic nature of these diseases but also the nature 
of their treatment.  Musculoskeletal diseases, injuries and diabetes top the list of 
demand for medical and other health professional services.  
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Figure 3: Distribution of costs by health sector, NHPA and all diseases, Australia 2000–01 
 
2.3 Expenditure by age and sex 
Health system expenditures allocated by disease are 26% higher for females than for 
males—$27.4 billion compared with $21.8 billion.  Expenditure per person is $2,821 
for females which is 24% higher than the $2,277 for males (Table 7). When maternal 
conditions are excluded, expenditure per person for females is 18% higher than for 
males. 
Expenditure per person is higher for females than males for disease groups such as 
the nervous system, musculoskeletal diseases and oral health.  It is higher for males 
for the cardiovascular, cancer and injury groups.  
Health expenditure per person is $2,426 on average per year for males aged 0 to 4 years.
It then decreases to $1,146 for boys aged 5 to 14 years and from there increases 
with age to $10,719 for men aged 75 years and over.  For females, the pattern is the 
same for children, but in adulthood expenditure peaks in the 25–34 years age group, 
reflecting child-bearing expenditure; it then declines for the age range 35 to 44 years 
and from there increases steadily with age to $11,346 per year for women aged  
75 years or over.  
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Table 7:  Allocated health expenditure per person by age, sex and burden of disease chapter, 
Australia, 2000–01 
Age (years) 
Burden of disease chapter 
and sex 0–4 5–14 15–24 25–34 35–44 45–54 55–64 65–74 75+ Total 
Cardiovascular           
Male 128 33 43 48 94 228 552 1,090 1,969 285 
Female 316 12 20 50 88 193 363 718 1,735 274 
Neoplasms           
Male 39 13 18 54 42 126 269 602 951 147 
Female 22 17 27 46 89 183 245 381 492 135 
Musculoskeletal           
Male 61 50 102 155 185 230 345 500 855 213 
Female 71 35 94 132 181 269 395 598 1,373 277 
Nervous system           
Male 178 70 48 68 76 115 167 439 1,747 189 
Female 127 57 66 72 80 121 166 493 2,862 309 
Oral health(b)            
Male 50 319 197 63 72 67 142 188 109 138 
Female 39 588 293 109 136 125 181 217 114 214 
Injuries           
Male 181 160 339 235 173 165 211 298 694 238 
Female 111 132 137 119 126 143 165 300 812 191 
Maternal conditions           
Female 9 1 236 541 152 2 0 0 15 137 
Other causes(a)           
Male 1,790 502 611 677 721 867 1,272 2,074 4,394 1,067 
Female 1,552 452 847 1,015 983 1,124 1,484 2,136 3,945 1,282 
Total           
Male 2,426 1,146 1,357 1,300 1,363 1,798 2,958 5,191 10,719 2,277 
Female 2,248 1,294 1,721 2,083 1,835 2,160 2,998 4,842 11,346 2,821 
Female (excl. maternal) 2,238 1,293 1,485 1,542 1,683 2,158 2,998 4,842 11,332 2,684 
Notes 
(a)  ‘Other causes’ includes infectious & parasitic, respiratory, neonatal causes, diabetes mellitus, endocrine, nutritional & metabolic, mental 
disorders, digestive system, genitourinary, skin diseases, congenital anomalies, and signs, symptoms, ill-defined conditions and other 
contact with health system. 
(b)  Age–sex splits of expenditure are preliminary estimates. 
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Figure 4: Allocated per capita health expenditure by disease and injury group and sex, Australia, 
2000–01 ($) 
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Figure 5: Allocated health expenditure by age and sex, Australia, 2000–01 ($ million) 
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Figure 6: Allocated health expenditure per person by age and sex, Australia, 2000–01 ($ million) 
 
2.4 Changes from 1993–94 to 2000–01 
Total recurrent expenditure on health goods and services in Australia in 2000–01 was 
estimated at $57.3 billion (8.6% of GDP), of which $49.2 billion could be allocated by 
disease.  For 1993–94 total recurrent health costs were $34.1 billion (7.7% of GDP), of 
which $31.4 billion was allocated by disease.  For 1993–94, expenditure on 
administration, public health and non-institutional services not elsewhere classified 
were allocated by disease; these categories were not allocated in 2000–01. Thus, to 
enable better comparisons, the data that follow for 1993–94 do not allocate 
administrative, public health expenditure and other non-institutional expenditure 
not elsewhere classified.  
The estimate of health expenditure allocated to diseases for 1993–94 that is 
comparable with 2000–01 is almost $30 billion (Table 1). After adjustment for health 
price inflation of 20%, the allocated health system cost for 1993–94 in 2000–01 prices 
was $36.0 billon. Therefore, between 1993–94 and 2000–01 the growth in inflation-
adjusted expenditure was from $36.0 to $49.2 billion --- $13.2 billion, or 37%. This 
represents an average annual increase of 4.6%.  The Australian population grew by 
10% during the period, an average annual increase of 1.4%. 
Because expenditure has been adjusted for overall health price inflation between 
1993–94 and 2000–01, it is possible to compare the specific disease expenditures for 
these two years and to examine the differences in growth for the different disease 
groups (Table 8).  
Between 1993–94 and 2000–01 there was a 66% increase in inflation-adjusted 
expenditure allocated to the category ‘Signs, symptoms, ill defined conditions and 
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other contact with the health system’.  This partly reflects changes in methods 
between 1993–94 and 2000–01, though it also reflects a relative increase in diagnostic 
expenditure. The growth in inflation-adjusted expenditure in all areas excluding this 
category was 33%.   
Areas that showed above-average growth from 1993–94 to 2000–01 were nervous 
system disorders (44%), digestive system diseases (38%) and oral health (52%). Areas 
which showed below-average growth were respiratory diseases (22%) mental 
disorders (32%), cardiovascular disease (26%) and neoplasms (31%). 
The growth of only 32% for mental disorders is affected by the fact that community 
health expenditure was not able to be allocated by disease, so the considerable 
increase in community mental health expenditure since 1993–94 is not included in 
these numbers. If this is included, the growth is 43%. 
The lower birth rate led to below-average growth for maternal conditions, neonatal 
causes and congenital anomalies.  
Expenditure on pharmaceuticals (67% growth) and dental services (50%) grew 
significantly faster in inflation adjusted terms than expenditure in other sectors. 
Hospital expenditure grew by 31% and expenditure on aged care homes grew by 
23% in inflation-adjusted terms. Not all diseases showed this pattern of high growth 
for pharmaceuticals and lower growth in hospitals and aged care homes. The 
nervous system category showed a 89% increase in aged care homes expenditure 
compared with a 46% increase in pharmaceutical expenditure. This is the result of 
the large increase in expenditure on care for people with dementia in aged care 
homes. For the injuries category, pharmaceuticals increased only 24% and hospitals 
increased a much higher amount (42%).  In contrast, for cardiovascular diseases the 
increase for hospitals was 27% compared with an increase for pharmaceuticals of 
62%. (Note that cholesterol-lowering drugs are classified as part of the ‘Endocrine’ 
category not ‘Cardiovascular’. If these were included with cardiovascular diseases, 
the pharmaceutical expenditures for cardiovascular disease would show an even 
greater increase.)   
Although the numbers in Table 8 have been adjusted to make 1993–94 as comparable 
as possible with 2000–01, there are differences in the classification systems and the 
methods used in the two years, so the comparisons must be recognised as 
approximate only.    
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Table 8: Change in inflation-adjusted(a) health system expenditure, 1993–94 to 2000–01 
Hospital Aged care homes Pharmaceuticals Dental services Other(a) Total 
Burden of disease chapter (per cent) 
$ million 
(2000–01 
prices) 
Infectious & parasitic 62 n.a. n.a. n.a. n.a. 28 274 
Respiratory 44 n.a. 16 n.a. 11 22 636 
Maternal conditions 4 n.a. n.a. n.a. 104 9 110 
Neonatal causes and congenital anomalies 22 n.a. n.a. n.a. 169 28 126  
Neoplasms 25 n.a. n.a. n.a. 23 31 651 
Diabetes mellitus 151 60 87 n.a. 135 118 453 
Endocrine, nutritional & metabolic 37 –64 158 n.a. 33 65 620 
Mental disorders 10 16 160 n.a. 29 32 729 
Nervous system 7 89 46 n.a. 30 44 1,490 
Cardiovascular 27 –25 62 n.a. 31 26 1,118 
Digestive system 31 –18 106 n.a. 19 38 776 
Musculoskeletal 26 –7 108 n.a. 50 37 1,276 
Oral health 128 n.a. n.a. 50 n.a. 52 1,151 
Injuries 42 –22 24 n.a. 33 36 1,072 
Signs, symptoms, ill-defined conditions and other 
contact with the health system(c) 64 n.a. 99 n.a. n.a. 66 2,214 
Total 31 23 67 50 34 37 13,161 
$ million (2000–01 prices) 5,149 721 3,233 1,021 3,035 13,161  
(a)  1993–94 expenditures have been converted to 2000–01 prices using the total health price deflator (AIHW 2003:67). 
(b)  Includes out-of-hospital medical, other health professionals and research. 
(c)  ‘Signs, symptoms and ill-defined conditions’ includes diagnostic and other services for signs, symptoms and ill-defined conditions where the cause of the problem is unknown. ‘Other contact with the health system’ 
includes fertility control, reproduction and development; elective plastic surgery; general prevention, screening and health examination; and treatment and aftercare for unspecified disease.  
n.a.   Not applicable. Growth rate not displayed as methodology changed between the two years, numbers too small to be meaningful or zero in both years.
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3 Conclusion 
This is the second comprehensive national report on health expenditure by disease 
group.  Its aim is to provide an overview as well as a systematic, comprehensive 
analysis of the total health system costs of disease and injury in Australia during 
2000–01, based on the best possible estimates of health system resources directed at 
the prevention and treatment of diseases and injuries.  
Cardiovascular diseases represent the most expensive group ($5.4 billion), and also 
account for a high proportion of deaths—38% (Table 3). 
Expenditure for nervous system disorders has shown a very large increase since 
1993–94—mainly because of the increase in expenditure on Alzheimer’s disease and 
other dementias, which is strongly affected by the growth and ageing of the 
population.  
The seven National Health Priority Areas (NHPAs) account for $21.4 billion, or 
43.5% of allocated health system expenditure.  
Expenditure per person is $2,821 for females, which is 24% higher than the $2,277 for 
males. 
Health expenditure per person is $2,426 on average per year for males aged 0 to 4 
years. It then decreases to $1,146 for boys aged 5 to 14 years and from there increases 
steadily with age to $10,719 for men aged 75 years and over.  For females, the pattern 
is the same for children but in adulthood expenditure peaks in the 25–34 years age 
group, reflecting child-bearing and health expenditure related to the genitourinary 
system; it then declines for the age range 35 to 44 years and from there increases with 
age to $11,346 for women aged 75 years or over.  
The following points should be borne in mind when considering these results: 
• This study is a sequel to the 1993–94 study, so methods used and the source of 
data used for the estimations have in most cases remained the same to enable 
comparison over time. 
• The costs are direct costs only; indirect costs, caregiver costs and other intangible 
costs are not included. 
• It has been possible to allocate only 86% of recurrent health expenditures by 
disease. The costs estimated for each disease group are therefore conservative. 
Furthermore, cost-of-illness studies such as this only provide estimates of the impact 
of a disease on health system expenditures. Because they describe only the monetary 
burden of treating and/or preventing a disease, they cannot provide a measure of 
the extent to which this burden can be alleviated or the resulting cost savings that 
would be achieved; nor can they suggest how much should be spent on prevention 
and treatment.  
Expenditure for each disease category that is included in this publication gives a 
picture of expenditure that is more clinically relevant than expenditure split only by 
administrative category:  the administrative category view of expenditure is subject 
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to the vagaries of the way the health system happens to be organised at a particular 
point in time.  
It is important to understand that expenditure is an input measure only, and inputs 
are but one part of the health system. The output and outcomes that derive from this 
expenditure and from other inputs are also of relevance. The output data for each 
disease category—e.g. the number of separations and bed-days, medical services and 
pharmaceutical scripts used—will be published at a later date.  
In addition, information on disability and death that arise through disease and injury 
will be published as part of the Australian burden of disease project. The burden of 
disease was first estimated for Australia for 1996—see AIHW: Mathers  et al.(1999).  
These estimates are now being updated through joint work by the University of 
Queensland and the Australian Institute of Health and Welfare, and will be released 
progressively during the next 18 months.  
Expenditure data, output data and burden of disease data together can be used to 
provide a broad picture of the workings of the health system. For example, 
expenditure on cancer treatment and prevention over time can be compared with the 
changes in the number of hospital separations, medical services used and 
pharmaceuticals dispensed for cancer, and with the improvements in health status.    
This report will be of interest to anyone involved in resource allocation, including 
health policy makers at commonwealth, state and local government levels, health 
planners and administrators, community and hospital practitioners and academic 
researchers, as well as the general public. 
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